These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38082476)

  • 1. Progress of SARS-CoV-2 Main protease peptide-like inhibitors.
    Liu X; Ren X; Hua M; Liu F; Ren X; Sui C; Li Q; Luo F; Jiang Z; Xia Z; Chen J; Yang B
    Chem Biol Drug Des; 2024 Jan; 103(1):e14425. PubMed ID: 38082476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
    Goyal B; Goyal D
    ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
    Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy.
    Mohammad T; Shamsi A; Anwar S; Umair M; Hussain A; Rehman MT; AlAjmi MF; Islam A; Hassan MI
    Virus Res; 2020 Oct; 288():198102. PubMed ID: 32717346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-silico guided design, screening, and molecular dynamic simulation studies for the identification of potential SARS-CoV-2 main protease inhibitors for the targeted treatment of COVID-19.
    Gutti G; He Y; Coldren WH; Lalisse RF; Border SE; Hadad CM; McElroy CA; Ekici ÖD
    J Biomol Struct Dyn; 2024; 42(4):1733-1750. PubMed ID: 37114441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 M
    Citarella A; Scala A; Piperno A; Micale N
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
    Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
    Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deciphering the binding mechanism of inhibitors of the SARS-CoV-2 main protease through multiple replica accelerated molecular dynamics simulations and free energy landscapes.
    Li M; Liu X; Zhang S; Liang S; Zhang Q; Chen J
    Phys Chem Chem Phys; 2022 Sep; 24(36):22129-22143. PubMed ID: 36082845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biflavonoids from
    Lokhande K; Nawani N; K Venkateswara S; Pawar S
    J Biomol Struct Dyn; 2022 Jul; 40(10):4376-4388. PubMed ID: 33300454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
    Martorana A; Gentile C; Lauria A
    Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel
    Sencanski M; Perovic V; Pajovic SB; Adzic M; Paessler S; Glisic S
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32842509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Updated Review on SARS-CoV-2 Main Proteinase (M
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conventional Understanding of SARS-CoV-2 M
    Zhou K; Chen D
    Chembiochem; 2023 Nov; 24(22):e202300301. PubMed ID: 37577869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analyzing 3D structures of the SARS-CoV-2 main protease reveals structural features of ligand binding for COVID-19 drug discovery.
    Xu L; Chen R; Liu J; Patterson TA; Hong H
    Drug Discov Today; 2023 Oct; 28(10):103727. PubMed ID: 37516343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure of M
    Jin Z; Du X; Xu Y; Deng Y; Liu M; Zhao Y; Zhang B; Li X; Zhang L; Peng C; Duan Y; Yu J; Wang L; Yang K; Liu F; Jiang R; Yang X; You T; Liu X; Yang X; Bai F; Liu H; Liu X; Guddat LW; Xu W; Xiao G; Qin C; Shi Z; Jiang H; Rao Z; Yang H
    Nature; 2020 Jun; 582(7811):289-293. PubMed ID: 32272481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors.
    He J; Hu L; Huang X; Wang C; Zhang Z; Wang Y; Zhang D; Ye W
    Int J Antimicrob Agents; 2020 Aug; 56(2):106055. PubMed ID: 32534187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of SARS-CoV-2 Main Protease Inhibitors from a Library of Minor Cannabinoids by Biochemical Inhibition Assay and Surface Plasmon Resonance Characterized Binding Affinity.
    Liu C; Puopolo T; Li H; Cai A; Seeram NP; Ma H
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.